Developer docs
API playgroundTry for free, no card

Search company profiles

Blueprint Genetics

Full company profile

uuid0002oes

Namestring
Blueprint Genetics
Legal namestring
Blueprint Genetics Oy
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Blueprint Genetics is a clinical genetic testing laboratory headquartered in Espoo (Helsinki), Finland, founded in 2012. The company provides next-generation sequencing (NGS)-based diagnostic genetic testing services to healthcare providers — including clinicians, genetic counselors, and hospitals — across more than 70 countries, with all sample processing performed in its CAP-accredited, CLIA-certified laboratory in Helsinki. Its core portfolio includes over 220 diagnostic NGS panels spanning 14 medical specialties (cardiology, neurology, hereditary cancer, metabolic disorders, ophthalmology, etc.), Whole Exome Sequencing (WES) with a proprietary genotype-first analysis approach, single gene tests, variant-specific testing, and reproductive screening tests including FMR1 repeat expansion analysis.

The company's technical stack is built on Illumina NovaSeq instrumentation with an in-house designed WES platform and a proprietary bioinformatics pipeline. Differentiated features include high-coverage WES (174X median depth, ≥99.4% of bases covered at ≥20X), industry-leading analytical sensitivity (99.7% SNV sensitivity, >99.99% specificity), comprehensive mitochondrial genome analysis, and coverage of approximately 1,500 non-coding disease-causing variants in every WES. The company has expanded its diagnostic customization gene list by over 14,000 genes to support bespoke panel design.

Revenue is generated predominantly through per-test unit pricing on a pay-as-you-go basis, with tiered pricing visible (e.g., $1,750 per test for select panels). Orders are placed via the HIPAA-compliant Nucleus online portal or paper requisition forms, with specimen collection kits shipped globally and samples returned to the Helsinki lab. The company supplements its core diagnostic offering with ancillary services — Variant Reevaluation, VUS Clarification, Clinical Genetics Support, and a premium Express Service with a two-week turnaround time. Across 2014–2020, Blueprint Genetics raised approximately $26 million in disclosed venture funding from investors including Inventure, Creathor Ventures, MTIP AG, Pontos Group, Tekes Venture Capital, and Stanford University.

Short descriptiontext

Blueprint Genetics is a Finland-based clinical genetic testing laboratory founded in 2012 that provides NGS-based diagnostic panels, whole exome sequencing, and reproductive screening tests to healthcare providers in over 70 countries, operating a CAP-accredited, CLIA-certified lab with proprietary bioinformatics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEspoo, Finland
HQ citystring
Espoo
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genetic testing, next generation sequencing, whole exome sequencing, rare disease diagnostics, hereditary cancer panels
Industry4 codes
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Genetic Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Genetic Diagnostic Testing Services
TypeOne Time License
Description

Blueprint Genetics generates revenue through laboratory diagnostic genetic testing services including panels (over 220 panels across 14 medical specialties), Whole Exome Sequencing (WES), Single Gene Tests, and Variant Specific Testing. Services are sold to healthcare providers who order tests for their patients.

blueprintgenetics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Neonatal Respiratory Distress - Surfactant Dysfunction Panel (PU0501)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Tier 4: $1,750 per test. For specific panel pricing inquiries, contact billing team at billing.us@blueprintgenetics.com.

blueprintgenetics.com
2Express Service
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Express Service available for an additional charge on top of standard test pricing. Provides 2-week turnaround time vs standard 3-6 weeks. Contact local Blueprint Genetics representatives for specific pricing.

blueprintgenetics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Blueprint Genetics provides clinical-grade genetic diagnostic testing services to healthcare providers, offering over 220 NGS panels across 14 medical specialties, Whole Exome Sequencing (WES), single gene tests, variant-specific testing, and reproductive screening tests. Tests are ordered through the Nucleus portal or paper requisitions, with samples processed at its CAP-accredited, CLIA-certified laboratory in Espoo, Finland.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • WES diagnostic yield of 20% to 60% in cases with severe, early-onset disorders
+3 more records
Product overview1 text field

Blueprint Genetics offers a comprehensive genetic testing portfolio spanning diagnostic panels across 14 medical specialties, Whole Exome Sequencing (WES), single gene tests, variant-specific testing, and screening tests. The core offerings include over 220 customizable NGS panels and WES with family analysis options. Supporting services include Variant Reevaluation, VUS Clarification, Clinical Genetics Support, and an Express Service for urgent cases. All services are accessible through the Nucleus online ordering platform.

Product and service8 records
1Diagnostic Panels
CategoryClinical Genetic Testing - Panels
Description

Next-generation sequencing (NGS) based multi-gene panels covering 14 medical specialties including Cardiology, Neurology, Pediatrics, Oncology, and more. Over 220 panels available with customizable options for healthcare providers diagnosing inherited conditions.

2Whole Exome Sequencing (WES)
CategoryClinical Genetic Testing - Whole Exome
Description

Comprehensive analysis of protein-coding regions of approximately 20,000 genes using a proprietary genotype-first approach. Includes Whole Exome Family Plus (proband with parents) and Whole Exome Plus (proband only) options with deletion/duplication analysis for healthcare providers.

3Single Gene Tests
CategoryClinical Genetic Testing - Single Gene
Description

Targeted testing for specific single genes when clinical presentation strongly indicates a particular condition. Offered to healthcare providers as a focused alternative to broad panel testing.

4Variant Specific Testing
CategoryClinical Genetic Testing - Variant Confirmation
Description

Includes Familial Variant Testing (FVT) and Targeted Variant Testing (TVT) for confirming variants identified in family members or previously identified in the proband. Used by healthcare providers for cascade family testing.

5Screening Tests
CategoryClinical Genetic Testing - Reproductive Screening
Description

Genetic screening products including Ashkenazi Jewish Reproductive Screen, Comprehensive Reproductive Screen, and Core Reproductive Screen - all with FMR1 repeat expansion options for carrier and reproductive screening.

6Mitochondrial Genome Test
CategoryClinical Genetic Testing - Mitochondrial
Description

Complete analysis of the entire mitochondrial genome including sequencing and copy number variant analysis for all 37 mtDNA genes. Available standalone or included in over 30 panels at no additional cost.

7Nucleus
CategoryOnline Ordering Platform
Description

HIPAA-compliant online ordering portal for healthcare providers to order tests, access patient test results, track order status, and manage genetic testing workflows.

8Express Service
CategoryLaboratory Service Tier
Description

Expedited testing service with a 2-week turnaround time for urgent diagnostic timelines. Available for all test types including Panels, WES, Screening Tests, and Variant-Specific Testing. Additional fee applies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical genetic testing laboratory offering exome, genome and panels across rare disease, pediatric and reproductive indications; direct competitor in clinical NGS diagnostics to healthcare providers.

TypeDirect peer
Description

Clinical genetic testing lab providing broad hereditary disease panels, exome sequencing and reproductive health testing; closest direct overlap with Blueprint's panel and WES portfolio.

TypeDirect peer
Description

Clinical genetic diagnostics lab with deep specialty coverage (cardiology, neurology, oncology, reproductive) and large panel/WES menu; competes head-to-head with Blueprint on rare-disease panels and WES.

TypeDirect peer
Description

Germany-based clinical genomics lab focused on rare disease diagnostics, WES/WGS and reproductive carrier screening; highly comparable European-headquartered peer with overlapping test menu and customer base.

TypeDirect peer
Description

US clinical genetic testing laboratory offering large panel catalog and whole exome sequencing for rare inherited disorders; comparable business model selling NGS-based diagnostics to clinicians.

TypeDirect peer
Description

Clinical NGS lab providing comprehensive genetic testing panels across many specialties with technology-driven custom panel design; overlapping platform-style offering to healthcare providers.

7PerkinElmer Genomics
TypeBroad incumbent
Description

Life-sciences tools and diagnostics arm of PerkinElmer offering clinical genomic testing services across rare disease, newborn screening and reproductive health; broader portfolio incumbent with overlapping test categories.

TypeBroad incumbent
Description

Established clinical genetics company with broad hereditary cancer, reproductive and pharmacogenomic testing; relevant incumbent competitor for Blueprint's hereditary cancer and reproductive panels.

TypeEmerging player
Description

Clinical genomics company with strong reproductive health (carrier/NIPT) and oncology focus; partial overlap in reproductive/carrier screening and hereditary cancer panels where Blueprint also competes.

10EGL Genetics (Eurofins)
TypeBroad incumbent
Description

Clinical molecular and cytogenetic diagnostics lab within the Eurofins network; broad menu of rare disease panels and WES overlapping Blueprint's clinical offerings across multiple specialties.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blueprint Genetics

Clinical Genetic Diagnosticsblueprintgenetics.com

Blueprint Genetics is a Finland-based clinical genetic testing laboratory founded in 2012 that provides NGS-based diagnostic panels, whole exome sequencing, and reproductive screening tests to healthcare providers in over 70 countries, operating a CAP-accredited, CLIA-certified lab with proprietary bioinformatics.

What Blueprint Genetics does

Blueprint Genetics is a clinical genetic testing laboratory headquartered in Espoo (Helsinki), Finland, founded in 2012. The company provides next-generation sequencing (NGS)-based diagnostic genetic testing services to healthcare providers — including clinicians, genetic counselors, and hospitals — across more than 70 countries, with all sample processing performed in its CAP-accredited, CLIA-certified laboratory in Helsinki. Its core portfolio includes over 220 diagnostic NGS panels spanning 14 medical specialties (cardiology, neurology, hereditary cancer, metabolic disorders, ophthalmology, etc.), Whole Exome Sequencing (WES) with a proprietary genotype-first analysis approach, single gene tests, variant-specific testing, and reproductive screening tests including FMR1 repeat expansion analysis.

The company's technical stack is built on Illumina NovaSeq instrumentation with an in-house designed WES platform and a proprietary bioinformatics pipeline. Differentiated features include high-coverage WES (174X median depth, ≥99.4% of bases covered at ≥20X), industry-leading analytical sensitivity (99.7% SNV sensitivity, >99.99% specificity), comprehensive mitochondrial genome analysis, and coverage of approximately 1,500 non-coding disease-causing variants in every WES. The company has expanded its diagnostic customization gene list by over 14,000 genes to support bespoke panel design.

Revenue is generated predominantly through per-test unit pricing on a pay-as-you-go basis, with tiered pricing visible (e.g., $1,750 per test for select panels). Orders are placed via the HIPAA-compliant Nucleus online portal or paper requisition forms, with specimen collection kits shipped globally and samples returned to the Helsinki lab. The company supplements its core diagnostic offering with ancillary services — Variant Reevaluation, VUS Clarification, Clinical Genetics Support, and a premium Express Service with a two-week turnaround time. Across 2014–2020, Blueprint Genetics raised approximately $26 million in disclosed venture funding from investors including Inventure, Creathor Ventures, MTIP AG, Pontos Group, Tekes Venture Capital, and Stanford University.

Blueprint Genetics firmographics

Firmographics
Name
Blueprint Genetics
Legal name
Blueprint Genetics Oy
Website
https://blueprintgenetics.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Blueprint Genetics is a Finland-based clinical genetic testing laboratory founded in 2012 that provides NGS-based diagnostic panels, whole exome sequencing, and reproductive screening tests to healthcare providers in over 70 countries, operating a CAP-accredited, CLIA-certified lab with proprietary bioinformatics.
Ownership category
akta.pro rank

Blueprint Genetics industry classification

Industry
Product category
Clinical Genetic Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Clinical genetic testing
  • Next generation sequencing
  • Whole exome sequencing
  • Rare disease diagnostics
  • Hereditary cancer panels

Where Blueprint Genetics is headquartered

Location

Headquarters

HQ city
Espoo
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Blueprint Genetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Genetic Diagnostic Testing Services: Blueprint Genetics generates revenue through laboratory diagnostic genetic testing services including panels (over 220 panels across 14 medical specialties), Whole Exome Sequencing (WES), Single Gene Tests, and Variant Specific Testing. Services are sold to healthcare providers who order tests for their patients.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goNeonatal Respiratory Distress - Surfactant Dysfunction Panel (PU0501)
Unit PricingPay-as-you-goExpress Service

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Blueprint Genetics product offering

Product offering

Core offering

Blueprint Genetics provides clinical-grade genetic diagnostic testing services to healthcare providers, offering over 220 NGS panels across 14 medical specialties, Whole Exome Sequencing (WES), single gene tests, variant-specific testing, and reproductive screening tests. Tests are ordered through the Nucleus portal or paper requisitions, with samples processed at its CAP-accredited, CLIA-certified laboratory in Espoo, Finland.

Product overview

Blueprint Genetics offers a comprehensive genetic testing portfolio spanning diagnostic panels across 14 medical specialties, Whole Exome Sequencing (WES), single gene tests, variant-specific testing, and screening tests. The core offerings include over 220 customizable NGS panels and WES with family analysis options. Supporting services include Variant Reevaluation, VUS Clarification, Clinical Genetics Support, and an Express Service for urgent cases. All services are accessible through the Nucleus online ordering platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Diagnostic Panels Next-generation sequencing (NGS) based multi-gene panels covering 14 medical specialties including Cardiology, Neurology, Pediatrics, Oncology, and more. Over 220 panels available with customizable options for healthcare providers diagnosing inherited conditions.
  • Whole Exome Sequencing (WES) Comprehensive analysis of protein-coding regions of approximately 20,000 genes using a proprietary genotype-first approach. Includes Whole Exome Family Plus (proband with parents) and Whole Exome Plus (proband only) options with deletion/duplication analysis for healthcare providers.
  • Single Gene Tests Targeted testing for specific single genes when clinical presentation strongly indicates a particular condition. Offered to healthcare providers as a focused alternative to broad panel testing.
  • Variant Specific Testing Includes Familial Variant Testing (FVT) and Targeted Variant Testing (TVT) for confirming variants identified in family members or previously identified in the proband. Used by healthcare providers for cascade family testing.
  • Screening Tests Genetic screening products including Ashkenazi Jewish Reproductive Screen, Comprehensive Reproductive Screen, and Core Reproductive Screen - all with FMR1 repeat expansion options for carrier and reproductive screening.
  • Mitochondrial Genome Test Complete analysis of the entire mitochondrial genome including sequencing and copy number variant analysis for all 37 mtDNA genes. Available standalone or included in over 30 panels at no additional cost.
  • Nucleus HIPAA-compliant online ordering portal for healthcare providers to order tests, access patient test results, track order status, and manage genetic testing workflows.
  • Express Service Expedited testing service with a 2-week turnaround time for urgent diagnostic timelines. Available for all test types including Panels, WES, Screening Tests, and Variant-Specific Testing. Additional fee applies.

Quantifiable outcome

  • WES diagnostic yield of 20% to 60% in cases with severe, early-onset disorders
  • +3 more outcomes

Companies that use Blueprint Genetics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Blueprint Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Blueprint Genetics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Blueprint Genetics competitors and assessment

Company assessment

Direct peers

  • GeneDx: Clinical genetic testing laboratory offering exome, genome and panels across rare disease, pediatric and reproductive indications; direct competitor in clinical NGS diagnostics to healthcare providers.
  • Invitae: Clinical genetic testing lab providing broad hereditary disease panels, exome sequencing and reproductive health testing; closest direct overlap with Blueprint's panel and WES portfolio.
  • Ambry Genetics: Clinical genetic diagnostics lab with deep specialty coverage (cardiology, neurology, oncology, reproductive) and large panel/WES menu; competes head-to-head with Blueprint on rare-disease panels and WES.
  • Centogene: Germany-based clinical genomics lab focused on rare disease diagnostics, WES/WGS and reproductive carrier screening; highly comparable European-headquartered peer with overlapping test menu and customer base.
  • PreventionGenetics: US clinical genetic testing laboratory offering large panel catalog and whole exome sequencing for rare inherited disorders; comparable business model selling NGS-based diagnostics to clinicians.
  • Fulgent Genetics: Clinical NGS lab providing comprehensive genetic testing panels across many specialties with technology-driven custom panel design; overlapping platform-style offering to healthcare providers.

Broad incumbents

  • PerkinElmer Genomics: Life-sciences tools and diagnostics arm of PerkinElmer offering clinical genomic testing services across rare disease, newborn screening and reproductive health; broader portfolio incumbent with overlapping test categories.
  • Myriad Genetics: Established clinical genetics company with broad hereditary cancer, reproductive and pharmacogenomic testing; relevant incumbent competitor for Blueprint's hereditary cancer and reproductive panels.
  • EGL Genetics (Eurofins): Clinical molecular and cytogenetic diagnostics lab within the Eurofins network; broad menu of rare disease panels and WES overlapping Blueprint's clinical offerings across multiple specialties.

Emerging players

  • Natera: Clinical genomics company with strong reproductive health (carrier/NIPT) and oncology focus; partial overlap in reproductive/carrier screening and hereditary cancer panels where Blueprint also competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Blueprint Genetics social profiles

Digital presence

Blueprint Genetics compliance and trust

Trust signal

Compliance2 records

Blueprint Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blueprint Genetics leadership team

Management profile

Number of profiles

Profiles6 records

Blueprint Genetics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blueprint Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blueprint Genetics

What does Blueprint Genetics do?

Blueprint Genetics provides clinical-grade genetic diagnostic testing services to healthcare providers, offering over 220 NGS panels across 14 medical specialties, Whole Exome Sequencing (WES), single gene tests, variant-specific testing, and reproductive screening tests. Tests are ordered through the Nucleus portal or paper requisitions, with samples processed at its CAP-accredited, CLIA-certified laboratory in Espoo, Finland.

Is Blueprint Genetics a public or private company?

Blueprint Genetics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Blueprint Genetics founded?

Blueprint Genetics was founded in 2012. It employs 101 to 250 people.

Where is Blueprint Genetics based?

Blueprint Genetics is headquartered in Espoo, Finland, in the Europe region.

How does Blueprint Genetics make money?

One revenue line is on record: genetic Diagnostic Testing Services.

Who are Blueprint Genetics's main competitors?

Direct peers on record are GeneDx, Invitae, Ambry Genetics, Centogene, PreventionGenetics and Fulgent Genetics. Broad incumbents are PerkinElmer Genomics, Myriad Genetics and EGL Genetics (Eurofins). Natera is listed as an emerging player.

Does Blueprint Genetics have an API?

No public API is recorded for Blueprint Genetics.

What industry is Blueprint Genetics in?

Blueprint Genetics's product category is Clinical Genetic Diagnostics. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGenetic Screening Testing for Preventive Health Market Top Companies Study - Exact Science, Labcorp Genetics Inc., Dante Labs US, Myriad Genetics, Inc., Blueprint Genetics.InsightAce Analytic released a market assessment report on the global genetic screening testing for preventive health market, forecasting 11.8% CAGR from 2025 to 2034. The report covers test types, technologies, applications, and end-users, with North America and Europe highlighted as key regions.DatamintelligencePredictive Genetic Testing And Consumer Wellness Genomics MarketThe global predictive genetic testing and consumer wellness genomics market is projected to grow at a CAGR of 14.3% from 2024 to 2031, driven by increasing health awareness and advancements in next-generation sequencing. North America currently holds the largest market share due to robust healthcare infrastructure, while Asia Pacific is identified as the fastest-growing region. Key industry participants include Illumina, ARUP Laboratories, and Blueprint Genetics, among others.PR NewswireQuest Diagnostics and Blueprint Genetics to Present New Insights from Genetic Testing at the 2021 Annual American College of Medical Genetics and Genomics Annual Clinical Genetics MeetingQuest Diagnostics and Blueprint Genetics presented results of 10 studies at the virtual 2021 American College of Medical Genetics and Genomics Annual Meeting, focused on enhancing the diagnostic process for inherited disorders through advanced genomic testing methods. These studies included significant findings in mitochondrial diseases, hearing loss, and skeletal dysplasias, highlighting the importance of comprehensive genetic testing in improving patient diagnosis and management. The collaboration aims to increase accessibility to genomic insights, thereby enhancing patient care and supporting drug development.GlobeNewswireAkouos and Blueprint Genetics Announce the Resonate Program to Improve Access to Genetic Testing for Individuals with Auditory NeuropathyAkouos and Blueprint Genetics announced the Resonate program, offering free genetic testing to eligible individuals with auditory neuropathy. The program includes a panel covering over 230 genes and free genetic counseling, with plans to expand beyond the U.S. in 2021.GlobeNewswireProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal DiseasesProQR Therapeutics joined the Foundation Fighting Blindness My Retina Tracker Program, which offers free genetic testing and counseling for inherited retinal diseases. The program has tested over 7,000 patients and includes a 285-gene panel. ProQR will gain access to patient data to advance treatments for conditions like Leber's congenital amaurosis and Usher syndrome.Nordic 9Blueprint Genetics was acquired by Quest Diagnostics.Quest Diagnostics acquired Blueprint Genetics, a Finnish genetic testing company, in an all-cash equity transaction with undisclosed financial terms. Blueprint Genetics, founded in 2012, serves customers in over 70 countries and was backed by more than $40 million in venture funding.PR NewswireQuest Diagnostics Acquires Blueprint Genetics to Broaden Access to Actionable Insights for Genetic and Rare DiseasesQuest Diagnostics announced the acquisition of Blueprint Genetics in an all-cash equity transaction, strengthening its advanced diagnostics and genetics offerings. Blueprint Genetics, founded in 2012 and headquartered in Helsinki, Finland, provides 3,900 targeted single gene and over 200 panel tests spanning 14 medical specialties, serving customers in over 70 countries. The acquisition is expected to yield new capabilities to serve providers specializing in rare disease and neurology, particularly pediatric and academic hospitals, while allowing Blueprint Genetics to leverage Quest's national infrastructure serving half the health systems and physicians in the United States.Nordic 9Blueprint Genetics secured more capital investment in the company.Blueprint Genetics, a Helsinki-based gene diagnostics company, completed a new capital investment round. Founded in 2012 as a Stanford spinoff, it covers over 2,500 genes and had EUR 15M in sales in 2018. Prior to this round, the company raised about $26M from outside investors.PR NewswireBC Platforms Partners with Blueprint Genetics to Provide Center of Excellence for Data Driven Testing Services in Rare DiseasesBC Platforms, a genomic data management and analytics company, announced a collaboration with Blueprint Genetics, a clinical genetic testing provider, to develop data-driven services for hospitals and the life sciences industry in rare diseases. The partnership combines Blueprint Genetics' clinical genetic testing capabilities with BC Platforms' data management platform to create an integrated system for genetic testing, clinical data applications, and precision medicine. Both companies expect the collaboration to improve patient outcomes, reduce healthcare operating costs, and accelerate time-to-discovery for rare inherited diseases.GlobeNewswireBlueprint Genetics, InformedDNA and the Foundation Fighting Blindness launch an open access program for patients with inherited retinal disease in the United StatesBlueprint Genetics, InformedDNA, and the Foundation Fighting Blindness launched an open-access program in October 2019 offering no-cost genetic testing and counseling for US patients with inherited retinal disease. The program expands the My Retina Tracker study, which has tested over 6,000 patients, and aims to test over 20,000 patients within a few years.